Subscribe
shutterstock_1516757639_grand_warszawski
Grand Warszawski / Shutterstock.com
3 December 2020GenericsRory O'Neill

Amgen, Teva to face Sensipar monopoly claims

Amgen and  Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar (cinacalcet) off the market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Fed Circ to rehear $235m ‘skinny label’ case
10 February 2021   The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report.
Generics
Teva sues two Indian generics over Huntington’s treatment
6 July 2021   Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Generics
Teva loses appeal to invalidate Korlym patent
9 December 2021   Teva Pharmaceuticals has failed to convince the US Court of Appeal for the Federal Circuit that a Corcept Therapeutics method patent for Korlym was invalid.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Fed Circ to rehear $235m ‘skinny label’ case
10 February 2021   The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report.
Generics
Teva sues two Indian generics over Huntington’s treatment
6 July 2021   Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Generics
Teva loses appeal to invalidate Korlym patent
9 December 2021   Teva Pharmaceuticals has failed to convince the US Court of Appeal for the Federal Circuit that a Corcept Therapeutics method patent for Korlym was invalid.

More on this story

Big Pharma
Fed Circ to rehear $235m ‘skinny label’ case
10 February 2021   The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report.
Generics
Teva sues two Indian generics over Huntington’s treatment
6 July 2021   Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Generics
Teva loses appeal to invalidate Korlym patent
9 December 2021   Teva Pharmaceuticals has failed to convince the US Court of Appeal for the Federal Circuit that a Corcept Therapeutics method patent for Korlym was invalid.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent